Try our Advanced Search for more refined results

Expert Analysis

Innovative Procedures V. Premarketing Approval

Law360, New York ( September 20, 2011, 12:23 PM EDT) -- The U.S. Food and Drug Administration is increasingly scrutinizing certain novel stem cell and tissue procedures used by physicians and companies, asserting that such activities do not comply with the Food, Drug and Cosmetic Act ("FDCA") and the Public Health Service Act ("PHSA"). One of the FDA's first test cases is against Regenerative Sciences LLC in the United States District Court for the District of Columbia (1:10-cv-01327-RMC). The decision by the court in this case will likely dictate how this nascent industry develops....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!